Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsIan G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
Estimating the term…
Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
1-32. (canceled)
A method for treating cancer comprising administering, to a patient in need thereof, a therapeutically effective amount of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate hydrochloride in at least one crystalline form chosen from Form 1, Form 2, Form 3A, Form 3B, Form 3C, Form 5, and Form 7.
A method for treating cancer comprising administering, to a patient in need thereof, a therapeutically effective amount of crystalline ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate hydrochloride Form 1.
A method for treating cancer comprising administering, to a patient in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate hydrochloride in at least one crystalline form chosen from Form 1, Form 2, Form 3A, Form 3B, Form 3C, Form 5, and Form 7.
Dependencies are inferred from the claim text.